Abbisko Cayman Limited (2256.HK) HKSE

18.05

-0.16(-0.88%)

Updated at September 08 03:43PM

Currency In HKD

Abbisko Cayman Limited

Address

Building 3, No. 898

Shanghai, 201203

China

Phone

86 21 6891 2098

Sector

Healthcare

Industry

Biotechnology

Employees

281

First IPO Date

October 13, 2021

Key Executives

NameTitlePayYear Born
Dr. Yao-Chang XuFounder, Chairman of the Board & Chief Executive Officer4.53M1957
Dr. Hongping YuCo-Founder, Jt Co Secretary, Senior Vice President of Chemistry, Chief Scientific Officer & Executive Director3.12M1968
Mr. Yongyi LiGeneral Counsel01976
Dr. Zhen ZhangVice President of CMC & Head of Chemistry, Manufacturing and Controls01973
Ms. Yin Wah Chan FCCA, FCIS, FCS, HKICSJoint Company Secretary01975
Dr. Zidong ZhangChief Financial Officer01981
Dr. Jing JiChief Medical Officer & Executive Director01971
Ms. Jia FengVice President of HR and Operations & Head of Human Resource0N/A

Description

Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in the People's Republic of China. Its product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. The company's primary product candidates are ABSK011, a small molecule inhibitor of fibroblast growth factor receptor 4 for the treatment of advanced hepatocellular carcinoma with hyper-activation of FGF19/FGFR4 signaling; and ABSK091, a molecularly targeted product candidate for the treatment of multiple solid tumors, including urothelial cancer, gastric cancer, cholangiocarcinoma, and lung cancer. It also has other pipeline product candidates. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.